ABT-639
- Generic Name
- ABT-639
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H20ClF2N3O3S
- CAS Number
- 1235560-28-7
- Unique Ingredient Identifier
- 0G7D0CQ88I
- Background
ABT-639 is under investigation in clinical trial NCT01345045 (A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain).
- Associated Conditions
- -
- Associated Therapies
- -
A Randomized, Double-blind, Placebo- and Active-controlled Study of the Electric Current Effects of ABT-639 on the Spontaneous Activity of Pain Sensory Receptors in Patients With Diabetic Peripheral Neuropathy
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-05-02
- Last Posted Date
- 2013-01-03
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 39
- Registration Number
- NCT01589432
- Locations
- 🇬🇧
Site Reference ID/Investigator# 68882, London, United Kingdom
A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2013-01-08
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 193
- Registration Number
- NCT01345045
- Locations
- 🇺🇸
Site Reference ID/Investigator# 51548, Dallas, Texas, United States
🇺🇸Site Reference ID/Investigator# 51302, Omaha, Nebraska, United States
🇺🇸Site Reference ID/Investigator# 52743, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath